Published November 15, 2021
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses incobotulinumtoxinA (Xeomin), powder for solution for injection, 50 and 100 units per vial.
- Indication: For the treatment of chronic sialorrhea associated with neurologic disorders in adults.